PLAINSBORO, N.J., Sept. 17, 2007 (PRIME NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq:IART) is pleased to announce the poster presentation "Periradicular Lumbar Fibrosis: What to Do?" by Dr. Inaki Arrotegui, of the Department of Neurosurgery, University of Valencia General Hospital, Spain, at this year's College of Neurological Surgeons Annual Meeting in San Diego. The presentation will take place this Monday, September 17th at 4 p.m. PST. This retrospective review of 430 patients, who underwent surgery of the lumbar spine, demonstrated that the re-operation rate significantly decreased for the population of patients who received DuraGen(R) Dural Graft Matrix as an adhesion barrier. The reduction in re-operation rate translated to a cost benefit to the hospital. Duragen Plus(R) has received approval in the European Union and Canada as a dural graft and adhesion barrier and is called DuraGen Plus(r) Adhesion Barrier Matrix. Duragen Plus(R) Adhesion Barrier Matrix is an investigational device in the United States.
